Like semaglutide or tirzepatide , side effects reported with retatrutide have been mostly GI in nature and most likely to occur after starting or increasing the dose
Christensen MB, Lund AB, Jrgensen NR, Holst JJ, Vilsbll T, Knop FK (2020) Glucose-dependent insulinotropic polypeptide (GIP) reduces bone resorption in patients with type 2 diabetes
Weight loss injections often require refrigeration and always a sharps container to properly and cleanly dispose of the used needle
Progress on this front was incremental and took many twists and turns
Individual results vary, but clinical studies have shown: Semaglutide : Patients may lose an average of 10% to 15% of their body weight over a 68-week period
Some trials involved split dosing twice per week